Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins

Prion

Volumn 4, Issue 1, 2010, Pages 26-31

  Kim, Jihoon ^a   Kobayashi, Masaki ^a   Fukuda, Makoto ^a   Ogasawara, Daisuke ^a   Kobayashi, Natsuki ^a   Han, Sungwoong ^a,b   Nakamura, Chikashi ^a,b   Inada, Masaki ^a   Miyaura, Chisato ^a   Ikebukuro, Kazunori ^a   Sode, Koji ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Amyloid fibril; Amyloid ; Cytotoxicity; Fibril formation; Inhibitor; Prion; Pyrroloquinoline quinone

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; PRION PROTEIN; PYRROLOQUINOLINEQUINONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FIBER; FLUORESCENCE ANALYSIS; GROWTH INHIBITION; MOUSE; NONHUMAN; PRION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM;

AMYLOID; ANIMALS; HUMANS; MICE; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; PQQ COFACTOR;

EID: 77949286151     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.4.1.10889     Document Type: Article

References (36)

1. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10:2-9.
2. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314:777-81.
3. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363-83.
4. Caughey B, Lansbury PT. Protofibrils, pores, fibrils and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26:267-98.
5. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006; 443:774-9.
6. Stites TE, Mitchell AE, Rucker RB. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr 2000; 130:719-27.
7. Killgore J, Smidt C, Duich L, Romero-Chapman N, Tinker D, Reiser K, et al. Nutritional importance of pyrroloquinoline quinone. Science 1989; 245:850-2.
8. Watanabe A, Tsuchida T, Nishigori H, Urakami T, Hobara N. Pharmacological Application of PQQ. In: Davidson VL, ed. Principles and Applications os Quinoproteins 1993; 395-408.
9. Kasahara T, Kato T. Nutritional biochemistry: A new redox-cofactor vitamin for mammals. Nature 2003; 422:832.
10. Zhang Y, Feustel PJ, Kimelberg HK. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat. Brain Res 2006; 1094:200-6.
11. Kobayashi M, Kim J, Kobayashi N, Han S, Nakamura C, Ikebukuro K, et al. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochem Biophys Res Commun 2006; 349:1139-44.
12. Zameer A, Schulz P, Wang MS, Sierks MR. Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry 2006; 45:11532-9.
13. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis 2005; 20:74-81.
14. Liu D, Xu Y, Feng Y, Liu H, Shen X, Chen K, et al. Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide. Biochemistry 2006; 45:10963-72.
15. Sabate R, Gallardo M, Estelrich J. An autocatalytic reaction as a model for the kinetics of the aggregation of beta-amyloid. Biopolymers 2003; 71:190-5.
16. Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, et al. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. Febs J 2005; 272:3661-72.
17. Moussa CE, Wersinger C, Tomita Y, Sidhu A. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Biochemistry 2004; 43:5539-50.
18. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem 2004; 279:25497-502.
19. Bocharova OV, Breydo L, Parfenov AS, Salnikov VV, Baskakov IV. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol 2005; 346:645-59.
20. Kirby L, Birkett CR, Rudyk H, Gilbert IH, Hope J. In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. J Gen Virol 2003; 84:1013-20.
21. Baskakov IV, Bocharova OV. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features. Biochemistry 2005; 44:2339-48.
22. Kobayashi M, Han S, Nakamura C, Sode K. Nanostructure fabrication based on engineered α-synuclein. NanoBioTechnology 2008; 4:50-5.
23. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006; 67:27-37.
24. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of alphasynuclein and disaggregates existing fibrils. J Biol Chem 2004; 279:26846-57.
25. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006; 97:105-15.
26. Kumar S, Mohanty SK, Udgaonkar JB. Mechanism of formation of amyloid protofibrils of barstar from soluble oligomers: evidence for multiple steps and lateral association coupled to conformational conversion. J Mol Biol 2007; 367:1186-204.
27. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998; 440:71-5.
28. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996; 35:13709-15.
29. Sode K, Ochiai S, Kobayashi N, Usuzaka E. Effect of Reparation of Repeat Sequences in the Human alpha-Synuclein on Fibrillation Ability. Int J Biol Sci 2007; 3:1-7.
30. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, et al. 3D structure of Alzheimer's amyloid-beta (1-42) fibrils. Proc Natl Acad Sci USA 2005; 102:17342-7.
31. Hornemann S, Korth C, Oesch B, Riek R, Wider G, Wuthrich K, et al. Recombinant full-length murine prion protein, mPrP(23-231): purification and spectroscopic characterization. FEBS Lett 1997; 413:277-81.
32. Smidt CR, Unkefer CJ, Houck DR, Rucker RB. Intestinal absorption and tissue distribution of [14C] pyrroloquinoline quinone in mice. Proc Soc Exp Biol Med 1991; 197:27-31.
33. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology - strategies for drug delivery to the brain. Curr Top Med Chem 2009; 9:182-96.
34. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamy-loidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004; 189:380-92.
35. Lundin A. Use of firefly luciferase in ATP-related assays of biomass, enzymes and metabolites. Methods Enzymol 2000; 305:346-70.
36. Slater K. Cytotoxicity tests for high-throughput drug discovery. Curr Opin Biotechnol 2001; 12:70-4.